Table 1 Patient characteristics and comparison between ICU survivors and decedents

Age in years, median [IQR]

73 [66–78]

74 [67–78]

70 [61–76]

0.133

0 (0)

Male gender, n (%)

44 (64)

31 (63)

13 (65)

1.000

0 (0)

Prior chemotherapy lines, n (%)

0.467

0 (0)

 0

7 (10)

4 (8)

3 (17)

 1

25 (37)

21 (43)

4 (22)

 2

20 (30)

13 (27)

7 (39)

 3

11 (16)

9 (18)

2 (11)

  ≥ 4

4 (6)

2 (4)

2 (11)

Prior chemotherapy lines, median [IQR]

2 [1–2]

1 [1–2]

2 [1–2]

0.728

0 (0)

Combination therapy, n (%)

23 (33)

18 (37)

5 (25)

0.342

0 (0)

Underlying disease, n (%)

0.218

0 (0)

 CLL

41 (59)

29 (59)

12 (60)

 DLBCL

9 (13)

9 (18)

0 (0)

 Others

19 (28)

11 (22)

8 (40)

Time between ibrutinib introduction and ICU admission in months, median [IQR]

6.6 [2.6–17.5]

8.3 [3.1–15.3]

6.2 [2.0–22.9]

0.956

2 (3)

Anti-pneumocystis prophylaxis, n (%)

40 (58)

29 (59)

11 (55)

0.960

2 (3)

Anti-viral prophylaxis, n (%)

45 (65)

34 (69)

11 (55)

0.390

2 (3)

Other comorbidities and additional infectious risk factors, n (%)

0 (0)

 Cardiovascular disease

41 (59)

31 (63)

10 (50)

0.323

 Chronic respiratory disease

12 (17)

8 (16)

4 (20)

0.691

 Chronic kidney disease

5 (7)

3 (6)

2 (10)

0.562

 Chronic liver disease

5 (7)

4 (8)

1 (5)

0.663

 Hypogammaglobulinemia

16 (23)

13 (27)

3 (15)

0.290

 Neutropenia

7 (10)

6 (12)

1 (5)

0.382

 Diabetes

13 (19)

8 (16)

5 (25)

0.619

 HIV

1 (1)

0 (0)

1 (5)

0.641

SOFA score at ICU admission, median [IQR]

5 [3–8]

4 [3–7]

7 [5–11]

0.004

2 (3)

Organ injuries at ICU admission, n (%)

 Respiratory

49 (71)

30 (61)

19 (95)

0.005

0 (0)

 Hemodynamic

34 (49)

22 (45)

12 (60)

0.262

0 (0)

 Liver

13 (19)

11 (22)

2 (10)

0.248

2 (3)

 Renal

23 (33)

14 (29)

9 (45)

0.205

0 (0)

 Neurological

30 (43)

18 (37)

12 (60)

0.083

0 (0)

 Multiorgan failure

47 (68)

31 (63)

16 (80)

0.173

2 (3)

Diagnostic group, n (%)

0.520

0 (0)

 Bacterial infection

45 (65)

34 (69)

11 (55)

 Fungal infection

13 (19)

8 (16)

5 (25)

 Viral infection

11 (16)

7 (14)

4 (20)

Polymicrobial infections

12 (17)

8 (16)

4 (20)

0,715

Organ support throughout ICU stay, n (%)

 Vasopressors

39 (57)

24 (49)

15 (75)

0.087

0 (0)

 IMV

28 (41)

15 (31)

13 (68)

0.010

0 (0)

 RRT

10 (15)

5 (10)

5 (25)

0.227

0 (0)

ICU length of stay in days, median [IQR]

5 [2–11]

6 [3–12]

3 [2–8]

0.105

0 (0)

Ibrutinib discontinuation in the ICU

57 (83)

41 (84)

16 (80)

0.691

0 (0)

Outcomes, n (%)

 ICU mortality

20 (29)

–

–

0 (0)

 Hospital mortality

32 (50)

12 (27)

–

5 (7)

 Day-90 mortality

35 (55)

15 (34)

–

5 (7)